We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

62 hedge funds and large institutions have $46.1M invested in Aclaris Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $33.4M → $46.1M (+$12.7M)

9.31% less ownership

Funds ownership: 77.28% → 67.97% (-9.3%)

13% less funds holding

Funds holding: 71 → 62 (-9)

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

43% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 21

Holders
62
Holders Change
-9
Holders Change %
-12.68%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
13
Reduced
21
Closed
21
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$670K
2
Millennium Management
Millennium Management
New York
+$516K
3
BCM
Bridgeway Capital Management
Texas
+$368K
4
Jane Street
Jane Street
New York
+$271K
5
SSA
Schonfeld Strategic Advisors
New York
+$233K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.12M
2
ECM
Endurant Capital Management
California
-$1.19M
3
MP
MFN Partners
Massachusetts
-$886K
4
State Street
State Street
Massachusetts
-$789K
5
EC
EcoR1 Capital
California
-$745K
Name Holding Trade Value Shares
Change 		Change in
Stake
Man Group
26
Man Group
United Kingdom
$151K – – –
AIM
27
Alambic Investment Management
California
$147K -$10.2K -7,600 -8%
State Street
28
State Street
Massachusetts
$126K -$789K -589,148 -88%
PP
29
Paloma Partners
Connecticut
$116K +$96.2K +71,800 New
HighTower Advisors
30
HighTower Advisors
Illinois
$113K – – –
Deutsche Bank
31
Deutsche Bank
Germany
$106K +$35.6K +26,605 +68%
Verition Fund Management
32
Verition Fund Management
Connecticut
$105K +$87.1K +65,000 New
Tudor Investment Corp
33
Tudor Investment Corp
Connecticut
$95K – – –
WG
34
Winton Group
United Kingdom
$73K -$94.7K -70,662 -61%
Cambridge Investment Research Advisors
35
Cambridge Investment Research Advisors
Iowa
$72K – – –
VF
36
Virtu Financial
New York
$61K +$50.2K +37,447 New
Goldman Sachs
37
Goldman Sachs
New York
$57K +$14.8K +11,026 +46%
Creative Planning
38
Creative Planning
Kansas
$49K – – –
Two Sigma Advisers
39
Two Sigma Advisers
New York
$42K -$11.8K -8,800 -25%
AG
40
Aperio Group
California
$35K +$3.34K +2,496 +13%
Charles Schwab
41
Charles Schwab
California
$34K -$86K -64,197 -76%
Morgan Stanley
42
Morgan Stanley
New York
$22K +$13K +9,724 +254%
LP
43
LMR Partners
United Kingdom
$22K +$18K +13,435 New
Dimensional Fund Advisors
44
Dimensional Fund Advisors
Texas
$18K – – –
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$17.3K +$32 +24 +0.2%
Barclays
46
Barclays
United Kingdom
$13K -$2.98K -2,222 -21%
Osaic Holdings
47
Osaic Holdings
Arizona
$8K – – –
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$7K -$4.76K -3,555 -45%
Bank of America
49
Bank of America
North Carolina
$7K +$4.68K +3,496 +392%
PA
50
Parallel Advisors
California
$6K – – –
1
2
3 4

ACRS Hedge Fund Activity: Q2 2020 in Review

62 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2020, worth a combined $46.1M — up 38% from $33.4M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ACRS and 12 opened new positions — a net loss of 9 holders — while 21 trimmed existing stakes and 13 added.

The largest buyer was Adage Capital Partners, adding an estimated $670K. The largest seller was BlackRock, cutting an estimated $2.12M.

  • 62 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2020, down from 71 in Q1 2020.
  • Funds reported $46.1M of Aclaris Therapeutics stock for Q2 2020, up 38% quarter-over-quarter.
  • 12 funds opened new Aclaris Therapeutics positions in Q2 2020 and 21 closed out, a net change of -9 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2020 was Adage Capital Partners, an estimated $670K added.
  • The largest Aclaris Therapeutics seller in Q2 2020 was BlackRock, an estimated $2.12M sold.

Based on aggregated 13F filings for Q2 2020.